156 related articles for article (PubMed ID: 16630038)
1. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy.
Lyons F; Hopkins S; Kelleher B; McGeary A; Sheehan G; Geoghegan J; Bergin C; Mulcahy FM; McCormick PA
HIV Med; 2006 May; 7(4):255-60. PubMed ID: 16630038
[TBL] [Abstract][Full Text] [Related]
2. Safety of nevirapine in pregnancy.
Natarajan U; Pym A; McDonald C; Velisetty P; Edwards SG; Hay P; Welch J; de Ruiter A; Taylor GP; Anderson J
HIV Med; 2007 Jan; 8(1):64-9. PubMed ID: 17305934
[TBL] [Abstract][Full Text] [Related]
3. Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya.
Peters PJ; Polle N; Zeh C; Masaba R; Borkowf CB; Oyaro B; Omolo P; Ogindo P; Ndivo R; Angira F; Lando R; Fowler MG; Weidle PJ; Thomas TK
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(2):142-9. PubMed ID: 22020069
[TBL] [Abstract][Full Text] [Related]
4. Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.
Giacomelli A; Riva A; Falvella FS; Oreni ML; Cattaneo D; Cheli S; Renisi G; Di Cristo V; Lupo A; Clementi E; Rusconi S; Galli M; Ridolfo AL
BMC Infect Dis; 2018 Nov; 18(1):556. PubMed ID: 30419834
[TBL] [Abstract][Full Text] [Related]
5. Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital.
Kondo W; Carraro EA; Prandel E; Dias JM; Perini J; Macedo RL; Cornelsen TC; Sbalquiero R; Sasaki Md
Braz J Infect Dis; 2007 Dec; 11(6):544-8. PubMed ID: 18327464
[TBL] [Abstract][Full Text] [Related]
6. Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
Peters PJ; Stringer J; McConnell MS; Kiarie J; Ratanasuwan W; Intalapaporn P; Potter D; Mutsotso W; Zulu I; Borkowf CB; Bolu O; Brooks JT; Weidle PJ
HIV Med; 2010 Nov; 11(10):650-60. PubMed ID: 20659176
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
Martínez E; Blanco JL; Arnaiz JA; Pérez-Cuevas JB; Mocroft A; Cruceta A; Marcos MA; Milinkovic A; García-Viejo MA; Mallolas J; Carné X; Phillips A; Gatell JM
AIDS; 2001 Jul; 15(10):1261-8. PubMed ID: 11426070
[TBL] [Abstract][Full Text] [Related]
8. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
Torti C; Costarelli S; De Silvestri A; Quiros-Roldan E; Lapadula G; Cologni G; Paraninfo G; Castelnuovo F; Puoti M; Carosi G;
Drug Saf; 2007; 30(12):1161-9. PubMed ID: 18035868
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
[TBL] [Abstract][Full Text] [Related]
10. Nelfinavir and nevirapine side effects during pregnancy.
Timmermans S; Tempelman C; Godfried MH; Nellen J; Dieleman J; Sprenger H; Schneider ME; de Wolf F; Boer K; van der Ende ME;
AIDS; 2005 May; 19(8):795-9. PubMed ID: 15867493
[TBL] [Abstract][Full Text] [Related]
11. Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
Snijdewind IJ; Smit C; Godfried MH; Nellen JF; de Wolf F; Boer K; van der Ende ME
J Infect; 2012 Apr; 64(4):409-16. PubMed ID: 22227465
[TBL] [Abstract][Full Text] [Related]
12. Liver toxicity after switching or simplifying to nevirapine-based therapy is not related to CD4 cell counts: results of the TOSCANA study.
Antela A; Ocampo A; Gómez R; López MJ; Mariño A; Losada E; Rodríguez R; Fernández R; Corredoira JC; Naval G; Rodríguez A; Miralles C; Prieto A; Gevihga Galician HIV Study Group
HIV Clin Trials; 2010; 11(1):11-7. PubMed ID: 20400407
[TBL] [Abstract][Full Text] [Related]
13. Third-trimester maternal toxicity with nevirapine use in pregnancy.
Joy S; Poi M; Hughes L; Brady MT; Koletar SL; Para MF; Fan-Havard P
Obstet Gynecol; 2005 Nov; 106(5 Pt 1):1032-8. PubMed ID: 16260522
[TBL] [Abstract][Full Text] [Related]
14. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
; de Vincenzi I
Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
[TBL] [Abstract][Full Text] [Related]
15. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.
Mocroft A; Staszewski S; Weber R; Gatell J; Rockstroh J; Gasiorowski J; Panos G; Monforte Ad; Rakhmanova A; Phillips AN; Lundgren JD;
Antivir Ther; 2007; 12(3):325-33. PubMed ID: 17591022
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.
Ouyang DW; Shapiro DE; Lu M; Brogly SB; French AL; Leighty RM; Thompson B; Tuomala RE; Hershow RC
AIDS; 2009 Nov; 23(18):2425-30. PubMed ID: 19617813
[TBL] [Abstract][Full Text] [Related]
17. Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.
Ouyang DW; Brogly SB; Lu M; Shapiro DE; Hershow RC; French AL; Leighty RM; Thompson B; Tuomala RE
AIDS; 2010 Jan; 24(1):109-14. PubMed ID: 19926957
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.
Jamisse L; Balkus J; Hitti J; Gloyd S; Manuel R; Osman N; Djedje M; Farquhar C
J Acquir Immune Defic Syndr; 2007 Apr; 44(4):371-6. PubMed ID: 17259905
[TBL] [Abstract][Full Text] [Related]
19. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.
Tseng YT; Yang CJ; Chang SY; Lin SW; Tsai MS; Liu WC; Wu PY; Su YC; Luo YZ; Yang SP; Hung CC; Chang SC
Int J Infect Dis; 2014 Dec; 29():12-7. PubMed ID: 25312984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
